Zydus Ahmedabad Biologics Plant Under USFDA Lens, Inspection Closes with 7 Observations
Written By : sheeba farhat
Published On 2026-05-07 17:37 GMT | Update On 2026-05-07 17:37 GMT
Advertisement
New Delhi: Zydus Lifesciences Ltd on Wednesday said US health regulator has completed inspection at group firm Zydus Biologics' injectable plant at Ahmedabad with seven observations.
The US Food and Drug Administration (USFDA) conducted GMP surveillance inspection at Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad, Zydus Lifesciences said in a regulatory filing.
The inspection was conducted from April 27, 2026 to May 5, 2026, it added.
"The inspection closed with seven observations. There were no data integrity related observations," the filing said.
The company will closely work with the USFDA to address the observations expeditiously, it added.
Also Read:Zydus Lifesciences Acquires France-Based Aptitude Orthopedie
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.